Dapagliflozin cardiovascular effects on end-stage kidney disease (DARE-ESKD-2) trial: rationale and design

PURPOSE. Sodium glucose co-transporter 2 inhibitors (SGLT2i) remarkably reduced the incidence of hospitalization for heart failure and cardiovascular death of conservatively managed chronic kidney disease. We hypothesized that adding SGLT2i to standard treatment would yield cardiovascular benefits a...

Descripción completa

Detalles Bibliográficos
Autores principales: Barreto, Joaquim, Martins, Marilia, Pascoa, Mauro, Medorima, Sheila T. K, Bonilha, Isabella, Jesus, Daniel Campos, Carbonara, Cinthia E. M., Quadros, Kelcia R. S., Assato, Barbara, Campos-Staffico, Alessandra M, Júnior, Gil Guerra, Nadruz, Wilson, de Oliveira, Rodrigo B., Sposito, Andrei C
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Journal Experts 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10602138/
https://www.ncbi.nlm.nih.gov/pubmed/37886458
http://dx.doi.org/10.21203/rs.3.rs-3434207/v1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10602138/
https://www.ncbi.nlm.nih.gov/pubmed/37886458
http://dx.doi.org/10.21203/rs.3.rs-3434207/v1

Ejemplares similares